NKX2-1 and cancer: CD274/PD-L1 that is induced by NKX2-1 has been a hallmark of cancer immunotherapy along with its receptor PD-1 (also known as PDCD1), which can be targeted by therapeutic antibodies that activate anti-tumorigenic T cells by blocking the interaction between CD274/PD-L1 and PDCD1/PD-131.